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Gene expressionCharcot–Marie–Tooth disease (CMT) is a heritable neurodegenerative condition, some types of which
(notably CMT4A) are caused by mutations in the GDAP1 gene that encodes a protein of unknown molecular
function implicated in regulation of mitochondrial ﬁssion. Here we present for the ﬁrst time a functional
analysis of the GDAP1 gene promoter which we found to be transcriptionally regulated by YY1, a broadly
studied factor that seems to be involved in regulating many of the same cellular phenomena as GDAP1. We
show that GDAP1 is broadly expressed in cancer cell lines of different tissue origin, contrasting with the
restricted neuronal distribution reported by some authors. There is a consensus YY1 binding site in the
GDAP1 core promoter which we show to be functional in both in vitro binding assays and in living cells.
Overexpression of YY1 activated the GDAP1 promoter in a reporter gene system as well as increased the level
of endogenous mRNA. RNAi-mediated knockdown of YY1 in HEK293 cells led to decreased GDAP1
expression. While YY1 is known to exert both positive and negative regulatory inﬂuences on nuclear-
encoded mitochondrial proteins, as well as on neurodegeneration-related genes, in all cell lines we studied
(including neuroblastoma) the effect of YY1 on GDAP1 expression is activatory. This leads to interesting
conclusions about the possible clinical role of this interaction and suggests a broader regulatory network.
© 2009 Elsevier Inc. All rights reserved.Introduction
The human GDAP1 gene encodes a protein (ganglioside-induced
differentiation associated protein 1) of 358 amino acids with
unknown molecular function; it is localized to the mitochondrial
outer membrane [1]. Mutations in the coding region of GDAP1 have
been identiﬁed as a major cause of peripheral neuropathy known as
Charcot–Marie–Tooth disease (CMT) [2,3] which affects both
Schwann cells (themyelinating glia of the peripheral nervous system)
and neurons [4]. CMT has a complex clinical presentation, most often
with progressive loss of sensation, muscle atrophy and loss of tendon
reﬂexes [5]. It also has an equally complex molecular genetics with
causative mutations for various forms found in as many as ten genes,
leading to autosomal and sex-linked, dominant and recessive
heredity. While it is usual to distinguish axonal and demyelinating
forms of CMT depending on whether neurons or Schwann cells are
predominantly affected by degeneration, it has been recently
suggested that this distinction is in no way absolute, with mutations
in the same gene yielding various clinical symptoms depending on
location of the mutation or even on other cellular environment-
related factors [6]. One of the more severe CMT forms is CMT4A, an
autosomal recessive CMT found to be exclusively linked to GDAP1
mutations and leading both to demyelination of nerves and eventualwski).
ll rights reserved.axonal damage, although not necessarily in the same patient [7].
While CMT4A is prominent for being one of the most common CMT
forms, GDAP1 mutations have recently been identiﬁed in other ones,
notably CMT2H and CMT2K (two dominant forms with predominant-
ly axonal manifestations) [8].
The molecular etiology of GDAP1 mutation-derived cellular
degeneration is virtually unknown. GDAP1 has been suggested to be
structurally related to the cytosolic glutathione S-transferases (GST)
but no functional evidence was found to conﬁrm this role [9]. GDAP1
is located in the outer mitochondrial membrane and overexpression
of active GDAP1 leads to mitochondria fragmentation, suggesting that
this protein is involved in the ﬁssion mechanism of mitochondrial
dynamics [7]. Changes in mitochondrial volume and efﬁciency have
recently been suggested as causal mechanisms in dominant forms of
GDAP1-linked CMT, but the evidence for this is largely circumstantial
[5]. There is a perceived lack of information onmolecular mechanisms
that could link GDAP1 expression and function—the present study
provides a valuable insight in this respect.
GDAP1 expression and its regulation in human body are still
virtually unknown; studies on distribution of rat Gdap1 gene products
(mRNA and protein) gave controversial and sometimes conﬂicting
results [7,10]. Regulation of nuclear genes encoding mitochondrial
proteins appears to ensue mostly by transcriptional mechanisms [11],
which may yield clues to function of the gene product due to the
preponderance of transcriptional networks and relative enrichment of
some response elements in mitochondrial gene promoters [12]. One
of them is the ubiquitous zinc ﬁnger transcription factor YY1 which
Table 1
Expression of GDAP1 and YY1 genes in cell lines of different origin.
Cell line (tissue origin) gene GDAP1 YY1
SH-SY5Y (neural) 97.1±1.6 99.3±1.9
HeLa (ovarian) 94.6±0.6 89.8±2.9
HepG2 (hepatic) 93.3±1.4 102.5±1.6
A549 (pulmonary) 50.3±1.5 60.1±2.1
HEK293 (renal) 36.0±1.9 60.6±0.8
Results are shown as copies of mRNA per housekeeping gene index (HPRT1, HMBS and
RPLI3A), mean±S.E.M., n=4.
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depending on the gene and cellular context [13]. YY1 controls
transcription of many mitochondrial genes including the most
ubiquitously expressed subunits of cytochrome c oxidase (COX)
[14,15]. With this in mind, we set out to analyze the activity of the
human GDAP1 promoter, especially with respect to YY1 transcription
factor binding site we identiﬁed.
Results
Computational analysis of GDAP1 promoter region
Promoter region prediction and gene analysis were performed
using the ElDorado and Gene2Promoter programs. One 745 bp
(−583/+162 bp) genomic DNA fragment were predicted by
Gene2Promoter software as the GDAP1 promoter region in the
Homo sapiens chromosome 8. The GDAP1 promoter region appeared
as a TATA-less, GC-rich region without canonical transcription
initiation site. Alignment of a 1079-bp fragment of 5′-ﬂanking regions
of GDAP1 gene from chimpanzee, orangutan, dog, mouse and rat
revealed that they share, respectively, 96.5%, 94.1%, 60.1%, 54.5% and
52.2% identity with the analogous human sequence. Matinspector
software identiﬁed numerous transcription factors binding sites
within this region. We concentrated on the most interesting and
relevant one—a 100% consensus response element for the YY1
transcription factor, spanning the translation start site and located
on the minus DNA strand. The alignment of this local sequence
element from human, chimpanzee, orangutan, dog, mouse and rat
GDAP1 promoters demonstrated a high degree of similarity and
conservation (Fig. 1). This suggests that GDAP1 expression might be
regulated in similar way across mammalian species.
GDAP1 and YY1 gene expression in human cell lines of different
tissue origin
First we decided to check the amount of GDAP1 mRNA in several
cell lines of different tissue origin using the real-time RT-PCR
technique to verify how it corresponds to the level of YY1 mRNA.
We found that level of GDAP1 transcript in all tested cells, contrary to
expectations, was rather highwith the following abundance ratio: 100
(SH-SY5Y): 97.4 (HeLa): 96.1 (HepG2): 51.5 (A549): 37.1 (HEK293)
(Table 1). This shows that the expression of GDAP1 is fairly similar
across various tissues, at least in cancer cell lines. The amount of YY1
transcript was comparable to GDAP1 (also relatively high)—differ-
ences between tested cell lines never exceeded 1.8-fold. It is worth
observing that the pattern of YY1 expression at least partially reﬂects
GDAP1mRNA level, with consistently the same two cell lines showing
lower expression.
Transcriptional activity of GDAP1 promoter in selected human cell lines
We constructed a GDAP1 luciferase reporter system bearing the
−843/+236 bp promoter sequence upstream from the ﬁreﬂy
luciferase gene. Based on the results of bioinformatic analysis of
possible transcription factor binding motifs, we generated a series ofFig. 1. Alignment of the human, chimpanzee, orangutan, dog, mouse and rat fragment of
GDAP1 promoter near the translational initiation site. YY1 consensus binding sequences
are overlaid on the wild type sequence with underlined conserved nucleotides.5′-deletion reporter constructs as illustrated in Fig. 2A. For the
analysis, we selected the three cell lines which represented various
levels of GDAP1 mRNA: high (SHSY5Y), moderate (A549) and low
(HEK294). The longest sequence, as predicted, did show strong
transcriptional initiation properties in three tested cell lines (Fig. 2B).
The relative transcriptional potency of the promoter was very similar
in all three lines for all construct lengths—it should be noted that the
differences in mRNA level between them have also been rather small.
The −9/+236 bp region of the GDAP1 promoter in all three cell
lines demonstrated an almost four times higher activity in the
luciferase reporter assay than the promoterless vector—pGL3-basic,
indicating that this 245-bp fragment contains the basal (core)
promoter where polymerase RNA II binds to initiate transcription
(Fig. 2B). Vector phGDAP1(−144/+236)Luc demonstrated the
highest transcriptional activity in all tested cell lines: 19-fold higher
activity over pGL3-Basic vector in SH-SY5Y and 14-fold higher in A549
and HEK293 cells. This region must be considered to contain a strong
enhancer-type binding site. Longer fragments of GDAP1 promoter
(representing sequences −399/+236 bp and −843/+236 bp) had
slightly, but signiﬁcantly lower activity than that observed for the
−144/+236 bp construct. These data suggest that potential
transcription repressor-binding sequences may be located within
the −399/−144 bp promoter region.
To verify whether the bioinformatically identiﬁed putative YY1
site is indeed functional, we performed a co-transfection experiment
where we caused the overexpression of YY1 in the presence of GDAP1
promoter constructs (since YY1 levels in all cells were rather high, we
chose to perform this experiment in the A549 cell line where YY1
expression is the lowest to start with). As shown in Fig. 3A, all cloned
fragments of GDAP1 promoter were able to respond in positive
manner (ca. 2-fold induction) to overexpression of the YY1 tran-
scription factor. As expected from the location of the YY1 consensus,
the shortest fragment of promoter (−9/+236 bp) was already fully
responsive to YY1. This, however, does not exclude the possibility of
the same factor interacting also with another site located more
distally.
To determine the actual contribution of this transcription factor to
regulation of GDAP1 promoter basal activity, we created a construct
with the YY1 binding site mutated within the−144/+236 bp (most
active) region of GDAP1 promoter. Mutation of YY1 binding site at
position −4/+8 did not change the basal level of transcriptional
activity of GDAP1 promoter (Fig. 3B), which shows that other
mechanisms contribute to this constitutive activity. It is possible, for
example, that factors which bind in the−144/−9 bp enhancer region
are as important to the basal activity as those binding in the core
promoter. The importance of the identiﬁed YY1 binding site was,
however, conﬁrmed by the fact that its mutation completely abolished
the ability of the reporter construct to respond to YY1 overexpression.
Ability of the YY1 transcription factor to bind the GDAP1 promoter
To test the ability of YY1 transcription factor to bind the GDAP1
promoter sequence, we initially used electromobility shift assay
(EMSA) on a consensus-containing probe derived from the natural
Fig. 2. Transcriptional activity of the human GDAP1 promoter. (A) Model of proximal fragment of the human GDAP1 gene promoter, 5′-deletion constructs and location of YY1
binding site. (B) Transcriptional activity of GDAP1 promoter constructs in cells of different tissue origin. Results of luciferase assay are standardized against control reporter activity
(co-transfected pCMV-SEAP containing secreted alkaline phosphatase coding sequence under control of CMV promoter) and expressed as fold induction over control value (activity
of promoterless pGL3-Basic vector) mean±S.E.M. (n=6).
409M. Ratajewski, L. Pulaski / Genomics 94 (2009) 407–413promoter sequence (−18/+17 bp). Incubation of the dissected DNA
fragment with nuclear extracts prepared from A549 cells produced
complexes with decreased mobility (Fig. 4). This represented a
sequence-speciﬁc interaction between the investigated fragment and
nuclear factors, since the formation of these complexes was
speciﬁcally reduced already with 40× molar excess of unlabeled
competitor probe with the same sequence as the labeled probe. We
also show that sequence speciﬁcity resides in the YY1 consensus itself
through the ﬁnding that competitor probe containing the mutated
consensus was not able to decrease binding even at 200× molar
excess. While this strongly hinted at YY1 being the interaction
partner, ﬁnal conﬁrmatory results were obtained using a speciﬁc
antibody against this factor. Addition of anti-YY1 antibody to the
binding reaction did not result in supershift, but reduced the protein–
DNA complex formation—antibody competition is typical for this
particular antibody, as seen also by other authors [16,17].
As a proof of actual direct binding of YY1 to GDAP1 promoter in
living cells, a chromatin immunoprecipitation (ChIP) assay was
performed. Immunoprecipitated GDAP1 promoter sequences were
quantitatively detected using real time PCR. We observed high
occupancy of GDAP1 by YY1 in all 3 tested cell lines (Table 2). There
were between 3.5 and 5 times more GDAP1 promoter sequences in
the samples immunoprecipitated with anti-YY1 antibody in compar-
ison to samples immunoprecipitated with negative control IgG
antibodies. A similar enrichment was not seen for GADPH promoter
sequences (used as negative control) in the same samples. This ﬁnally
conﬁrms that YY1 is indeed constitutively bound to the GDAP1
promoter in cell lines from various tissue backgrounds.
Endogenous GDAP1 as a target gene for YY1
To evaluate the role of YY1 factor in the regulation of GDAP1 gene
expression in living cells, we performed two types of experiments. Inthe ﬁrst assay, we caused the overexpression of YY1 in HEK293 cells (a
line with relatively low YY1 and GDAP1 levels) by transfection of its
cDNA-carrying expression vector (as a control, cells transfected with
empty vector pCMV-XL5 were used). As expected, transfection of YY1
cDNA caused a 25-fold increase of the amount of its mRNA (from the
value 61.6±1.37 to 1653.8±29.6), resulting in 1.74-fold induction of
GDAP1 mRNA level (from the value 40.6±1.16 to 70.4±1.37⁎⁎,
pb0.01). This quantitatively corresponds to results obtained in the
analogous promoter activity (reporter gene) assay. The relatively
weak induction is explained by the fact that YY1 is already highly
expressed even in this cell line and its binding site within the GDAP1
promoter is probably almost fully occupied in vivo. One has also to
bear in mind that in transient transfection experiments, the efﬁciency
of transfection with the expression construct is below 100%, while RT-
PCR results reﬂect mRNA abundance in material pooled from all cells
(including the non-transfected ones), increasing background.
If YY1 acts to induce GDAP1 gene expression, decreasing YY1 levels
should repress it. To test this hypothesis we used a second approach
where HEK293 cells were transfected with siRNA against YY1 to
reduce YY1 level. As shown in Fig. 5, RNA interference resulted in ca.
50% reduction of YY1 mRNA (again this value is affected by
transfection efﬁciency—the depression of YY1 level in actually
transfected cells was obviously higher), and it was accompanied by
a decrease of GDAP1 mRNA level by ca. 25%. Together these data
suggest that YY1 is indeed a functional transcriptional mediator of
normal GDAP1 mRNA expression in human cells.
Discussion
Mutations in the GDAP1 gene, both missense and nonsense ones,
have been shown as causal factors in CMT, mainly recessive CMT4A.
There are many unsolved questions about this disease: various
mutations may correspond to similar clinical symptoms, while family
Fig. 3. Reporter gene assay—YY1 induction of GDAP1 promoter activity. (A) Induction of transcriptional activity of the various GDAP1 promoter reporter constructs by overexpression
of YY1 (transiently co-transfected in the A549 cell line; pCMV-XL5 is the empty expression vector). ⁎⁎pb0.01, n=6. (B) Effect of mutation of YY1 binding site on response of the
GDAP1 promoter to YY1 overexpression in the A549 cell line; phGDAP1(−144/+236)Luc contains the wild-type sequence (wt), while phGDAP1m(−144/+236)Luc the mutated
one. ⁎⁎pb0.01, n=6.
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form of the condition. While initially described as a demyelinating
form with symmetric weakness and atrophy of appendages as the
clinical hallmark, pointing to a Schwann cell-related mechanism,
numerous cases with joint or even exclusive axonal presentations
(with vocal cord paresis as the deﬁning symptom) have since been
recorded. Because functional studies on GDAP1 sadly lag behind
mutation genetics, possibly much information on the causes of this
variant behavior could be gleaned from molecular genetics and
speciﬁcally frommechanisms of gene regulation. One crucial rationale
for interest in these mechanisms is the possibility that varying levels
of gene expression–caused e.g. by mutations in the non-coding
regulatory regions or by environmental interference with regulatory
signaling pathways–may underlie the clinical variability of disease
and its penetrability. Knowledge on regulatory mechanisms might
then conceivably allow us to devise treatment strategies in some
particular cases.
We turned to bioinformatics for hints on the possible regulatory
factors. In the considered fragment of GDAP1 promoter we have not
found any sequences that could account for potential preferentially
neuronal expression of this gene. Furthermore, potential binding sites
for numerous general factors identiﬁed by MatInspector software
(including e.g. ETS2, RELA, WT1, ELK1, RBPJ, EBF1 and ZBTB5) seemed
to be inactive when these factors were overexpressed in our reportergene system (data not shown). We were able to ﬁnd statistically
signiﬁcant induction of GDAP1 transcription only by one bioinforma-
tically identiﬁed protein—YY1. What is more, the YY1 binding site
within GDAP1 promoter has 100% identity with the consensus [18,13]
and is strongly conserved across mammalian species. It is located in
the reverse strand with the regard to direction of transcription—this
orientation has been already shown to be functional in other studies
[19,20].
Surprisingly, until now there have been no reports describing
GDAP1 transcriptional regulation even at the basal level, and even the
status of this gene in human tissues or cells other than neural [10].
GDAP1 has originally been identiﬁed as a ganglioside-induced gene,
but even the mode of this induction is not elucidated in any detail.
This adds signiﬁcance to our ﬁnding reported herein that GDAP1 is
ubiquitously and highly expressed in human cell lines of different
organ origin, including brain, liver, ovary, lung and kidney, with
relatively small (up to 3-fold) differences. Even though transformed
cell lines often differ signiﬁcantly from the original tissues they were
derived from, they are usually valid models for broad comparisons of
basic regulatory mechanisms of gene expression. Our ﬁndings were
virtually duplicated in a reporter gene system testing promoter
activity, with a similar pattern in all investigated cell lines. This
suggests that there is a strong, tissue-conserved mechanism respon-
sible for the basal level of GDAP1 transcription.
Fig. 5. Down-regulation of YY1 expression by siRNA leads to impairment of GDAP1 gene
expression in HEK293 cells measured by real-time PCR; results are presented relative to
a housekeeping gene index (calculated as averaged Ct of housekeeping genes HPRT1,
HMBS and RPLI3A), mean±S.E.M, ⁎⁎pb0.01, ⁎pb0.05, n=4.
Fig. 4. Results of EMSA performed on nuclear extracts from A549 cells with
ﬂuorescently labeled probe corresponding to a section of the wild-type GDAP1
promoter sequence. Numbers below scans represent densitometric quantiﬁcation of
the shifted (S) band in each lane (normalized to the value for sample containing only
probe and nuclear extract assumed as 100). “Cold probe” denotes ﬂuorescently
unlabelled competitor probes with wild-type (wt) or mutated (m) sequence and
numbers in its description represent molar fold excess of competitor with regard to
labeled probe. Sequences of wild type and mutated probes are shown with the YY1
consensus in bold and mutation site underlined.
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of YY1 involvement in basal GDAP1 regulation. YY1 expression across
cell lines partially reﬂected the pattern of expression of GDAP1mRNA.
To verify experimentally the possibility of functional importance for
this site, we performed co-transfection of GDAP1 promoter with YY1
cDNA and saw the upregulation of its activity. We also proved the
possibility of direct and speciﬁc binding of YY1 transcription factor to
the GDAP1 promoter in an EMSA-type assay. Introducing mutations in
the YY1 binding site of the human GDAP1 promoter prevented YY1
binding in EMSA and promoter activation in reporter gene assay.
The physiological relevance of our ﬁndings were proven by a series
of experiments on the endogenous GDAP1 gene. Firstly, ChIP assay
showed occupancy of YY1 on GDAP1 promoter in SH-SY5Y, A549 and
HEK293 cells; secondly, overexpression of YY1 in HEK293 cells caused
a signiﬁcant increase of GDAP1 mRNA. Additionally, we have shown
that speciﬁc knockdown of YY1 mRNA using siRNA duplexes resulted
in impairment of GDAP1 gene transcription. The overall conclusion
from the series of experiments is that YY1 is indeed a direct
transcriptional regulator of GDAP1 expression, responsible at least in
part for its high and broad basal level of expression, and its effect is
mediated by a well-deﬁned consensus binding site located in the core
promoter.Table 2
Results of chromatin immunoprecipitation experiments performed with anti-YY1
antibody in different cell lines.
Cell line Gene promoter Antibody Control IgG Anti-YY1
SHSY5Y GAPDH 38.1±5.7 51.1±4.4
GADP1 47.5±2.6 240.8±7.9⁎
HEK293 GAPDH 46.7±3.9 45.2±7.5
GADP1 53.3±6.3 210.2±5.6⁎
A549 GAPDH 31.5±2.8 39.3±1.2
GADP1 52.8±5.2 183.0±17.3⁎
Amount of immunoprecipitated cognate gene promoter sequences was determined by
real-time PCR and expressed in arbitrary relative values, standardized against amount
of input material (means±S.E.M., n=4).
⁎ Statistically signiﬁcant at pb0.01.The importance of our ﬁndings resides in the fact that we have
been able to link GDAP1–a gene with hitherto unknown regulation,
involved in a debilitating human disease–with YY1, an intensely
studied regulatory factor implicated in a plethora of cellular functions,
from basic proliferation and survival to differentiation and higher
functions in some cell types. We have shown for the ﬁrst time that
from the regulatory point of view, general (non-cell-line-type-
speciﬁc) mechanisms for the GDAP1 gene predominate over potential
nervous system-speciﬁc ones, contrary to what has been suggested
before on the basis of data derived from rats. This may represent a
species difference or just the divergence of approaches taken in the
different studies, including the limitations of our transformed cell line
model. We cannot exclude the possibility that factors acting at the
posttranslational level limit GDAP1 function exclusively to neural
tissue, leading to neurological manifestations of mutations in its gene.
Such kind of interactions (for muscle-speciﬁc protein function) have
already been reported in the literature [21]. Another possibility is that
the insufﬁciently investigated transcript variant 2 of GDAP1 (shorter,
containing an alternate in-frame exon) is a crucial player in CMT4A
and that the balance between transcript forms in the nervous system
needs to be investigated. From the point of view of YY1, it is important
to note that it is both a transcriptional activator and repressor, the
direction of its activity depending on the choice of cofactors and
posttranslational modiﬁcation of YY1 protein. Therefore, consistent
inducing activity towards GDAP1 described here in cell lines of
different lineages, where the repertoire of coactivators and corepres-
sors is markedly divergent, points to a more general mechanism,
interesting for studying YY1 function.
Another important facet of our discovery is that GDAP1 is known
to be a mitochondrial protein. It is known that YY1 regulates
numerous mitochondrial genes [22,12] and may be considered a key
factor in what has sometimes been termed the mitochondrial
regulatory network. The addition of GDAP1, a protein with an unclear,
but well-documented role in mitochondrial dynamics to the reper-
toire of YY1-regulated genes will certainly be highly interesting to
those researchers who consider YY1 to be a master regulator of this
organelle. There may be an important causal link between the fact
that YY1 is known to regulate the survival and death of some cell
types by inﬂuencing mitochondrial dynamics and the (until now
largely hypothetical) proposition that GDAP1 loss-of-function muta-
tions cause neurodegeneration via disruption of control over the
mitochondrial network. One must bear in mind that mitochondrial
homeostasis is important for all cells, but especially in axonal
degeneration the functional state of mitochondria is a crucial factor.
The relationship of YY1 with genes involved in neurological (and
speciﬁcally neurodegenerative) disease is also being studied intensely
at present [23]. It is notable as one of few transcription factors which
may be said to control the entire development of the nervous system,
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mice [23]. YY1 generally has confusing roles in differentiation: it
differentiates B cells and oligodendrocytes, but inhibits differentiation
of muscle and keratinocytes. However, in the nervous system, its
function is clearly differentiating. YY1 regulates the expression of
many neural-speciﬁc genes; it regulates the master regulator
(repressor) of neuronal development REST in a manner strikingly
similar to the one reported in the present study for GDAP1, with
analogous studies having been performed in SH-SY5Y [24].
YY1 has been shown to be a crucial factor in developmental
myelination of the central nervous system by induction of myelin-
speciﬁc proteolipid (Plp1) and Cko genes [25,26]. In neural crest (NC)
cells of the peripheral nervous system (a source of Schwann cells
which carry out peripheral myelination), YY1modulates transcription
of several genes (e.g. Snai2, Snai1, Otx2) that are important for their
differentiation and migration [23]. What is more, YY1 positively
regulates the transmembrane aspartyl protease BACE1 which is
crucial for the cleavage of neuregulin-1 into an active form, critical
in the myelination of peripheral nerves [27]. It is noteworthy that
demyelination of nerves is foremost among the symptoms of CMT4A,
so GDAP1 joins the number of myelination-related genes under direct
control from YY1. In that respect it is extremely interesting that mice
with conditional YY1 knockout in oligodendrocytes (including
Schwann cells) display demyelination with concomitant neurological
symptoms similar to CMT [26].
An interesting corollary to our discovery is the possible bearing it
has on the question of varying penetrability of CMT4A. YY1 is known
to respond to environmental stimuli, especially to genotoxic stress (it
is inhibited by PARP-mediated poly-ADP-ribosylation), which might
explain environmental impacts on disease severity. YY1 may also take
part in epigenetic regulatory mechanisms, again explaining different
penetrability of neurological conditions at the tissue level (axonal
degeneration vs. demyelination as result of GDAP1 loss-of-function in
different cell types) and at the level of various patients (sibling
differences, age of onset, etc.). The GDAP1 promoter is GC-rich, so
tilting the balance of histone modiﬁcations by recruiting HDACs or
HATs (both of which are known to be YY1 interactors) together with
variations in cytosine methylation may lead to GDAP1 gene hetero-
chromatinisation. This requires further study and is being currently
investigated by us.
In conclusion, we have proven the involvement of YY1 factor in the
regulation of a mitochondrial gene, GDAP1, that has a deﬁned role in
human neurological disease. YY1, in our opinion, is part of a
stimulatory complex that is responsible for maintenance of the
expression of GDAP1 gene in human cells, as evidenced by over-
expression experiments and RNAi. GDAP1 is in many ways prototypic
of YY1 targets: it is a mitochondrial protein with a neural function, it
has links to neurodegenerative disease and speciﬁcally to myelina-
tion, and has a constitutive, non-cell type-speciﬁc pattern of
expression. Our ﬁnding contributes crucial information on tissue-
speciﬁc expression of GDAP1 (although based on cell line comparison
rather than actual tissues) in light of its putative neural-speciﬁc
functions. It contributes the ﬁrst solid premise for assessing the
possible clinical importance of loss-of-expression or gene dosage
effects in the pathogenesis of CMT. On the other hand, this extends our
understanding of the role of YY1, especially in the nervous system,
providing potential explanations for the complexity of its effects.
Further studies, especially in actual differentiated cells (as opposed to
cancer cell lines), are now necessary.
Materials and methods
Cell culture
HepG2 (hepatocellular carcinoma), HeLa (ovary adenocarcinoma),
HEK293 (artiﬁcially transformed human embryonic kidney epithelialcells), A549 (alveolar epithelial non-small cell lung cancer) and SH-
SY5Y (neuroblastoma) human cell lines were obtained from ATCC
(Manassas, USA) and maintained in standard conditions (Dulbecco's
Modiﬁed Eagle's Medium or DMEM/F12Medium containing 10% fetal
bovine serum, 37 °C, 5% CO2).
Promoter constructs and transfections
All fragments of GDAP1 gene promoter were prepared by PCR
ampliﬁcation of human genomic DNA and cloned into pUC18 vector
using blunt end restriction endonuclease—SmaI. The following
primers were used for ampliﬁcation: downstream primer 5′-
GCCTGAAGCTTGTCAGGACACTGGAGGCG-3′ (position +236; all nu-
cleotide locations are reported relative to the A in the ATG translation
initiation codon) and upstream primers: 5′-CTAAGAGATCTTGCCTA-
CAACGTGACAGGG-3′ (−843), 5′-AACAAAGATCTAGGCTCCAAGAG-
CAACCC-3′ (−399), 5′-AGACTAGATCTCCGGCGAAACTACATTTCC-3′
(−144), 5′-CCGTGAGATCTCACCCCAAGATGGCTGAG-3′ (−9). Limits
of cloned promoter fragments for reporter gene constructs were
selected using bioinformatic analysis of the promoter to yield
fragments encompassing distinct putative response element group-
ings. Sequence of the cloned inserts was tested by automated
sequencing and then they were recloned into pGL3-Basic vector
(Promega, Madison, USA) using BglII and HindIII restriction endonu-
cleases, giving constructs phGDAP1(−843/+236)Luc etc. For trans-
fection of A549 and HEK293 cells, ExGen500 transfection reagent
(Fermentas) was used. SH-SY5Y cells were transfected with Fugene
HD reagent from Roche (Basel, Switzerland). Luciferase measure-
ments were performed as described [28] and standardized as
described [29].
Site-directed mutagenesis
Mutagenesis was performed directly on plasmids (pUC18)
containing 380 bp-long fragments of GDAP1 promoter (region
−144/+236) using the PCR based method followed by removal
of the template by DpnI digestion. For mutagenesis, the following
primer pairs were used: 5′-GTGCTCGCGCACCCCAAGCGTGCTGA-
GAGGCAGGA-3′(mf), 5′-TCCTGCCTCTCAGCACGCTTGGGGTGCG-
CGAGCAC-3′ (mr). The mutated sequence was veriﬁed by
automated sequencing and then recloned into pGL3-Basic vector
using BglII and HindIII restriction endonucleases to yield the
construct phGDAP1m(−144/+236)Luc.
Real time RT PCR
For mRNA abundance assay, total RNA was isolated from cells
using TRI Reagent® from Molecular Research Center (Cincinnati,
USA), reverse transcribed using RevertAid™ H Minus M-MuLV
Reverse Transcriptase (Fermentas) and anchored oligo-dT18 as
primers. Level of cognate cDNA was measured by real time PCR
ampliﬁcation performed on LightCycler 480 from Roche (Basel,
Switzerland) using the SYBRGreen I master mix (Roche) for
detection of PCR product. The following intron spanning primers
were used for detection of cDNA sequences: 5′-GCCTGTCCTTATC-
CACGG-3′ and 5′-GGCAAGGAGTCAAGCAGC-3′ for GDAP1, 5′-AGTGG-
GAGCAGAAGCAGG-3′ and 5′-TCATGGCCGAGTTATCCC-3′ for YY1
(designed using Primer3 software). Previously, using normalization
gene selection procedure of Vandesompele et al. [30], we selected
HPRT1, HMBS and RPLI3A as the most reliable reference genes for
the cell lines included in this study. Abundance of mRNA for a gene
of interest in samples was quantiﬁed by the ΔCt method as
described in detail previously [31]; for presentation and analysis,
ΔCt values were recalculated into relative copy number values
(number of copies of cognate gene mRNA per the housekeeping
gene index) as described previously [28].
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Chromatin immunoprecipitation was performed using the com-
mercially available EZ ChIP kit from Upstate (Charlottesville, USA)
according to manufacturer's instructions. The following antibodies
were used: normal Mouse IgG (part of the EZ ChIP kit), anti-YY1 (H-
414, Santa Cruz). The transcription factor-bound genomic DNA
fragments were quantiﬁed by real time PCR, using the following
primer pairs: complementary to the GAPDH promoter (part of the EZ
ChIP kit) as well as complementary to the GDAP1 promoter: 5′-
GCTTTCCAGTCGCAGACC-3′/ 5′-GCCTCTCAGCCATCTTGG-3′ (−185 to
+18 bp). Quantiﬁcation was done as previously described [28].
Nuclear extracts and EMSA
Nuclear extracts were prepared using a modiﬁcation of the
technique described by Dignam et al. [32] and subsequently used in
EMSA. EMSA was performed with infrared dye-labeled oligonucleo-
tide probes IRDye700-GDAP1 representing the sequence (top strand):
5′-GTGCTCGCGCACCCCAAGATGGCTGAGAGGCAGGA-3′ (wt). 2 μg of
A549 cell nuclear extract were incubated with 10 fmol of IRDye-
labeled probes in buffer containing: 5mMTris–HCl (pH=8.0), 50mM
NaCl, 5 mMDTT, 5 mMMgCl2, 0.5% Igepal, 25% glycerol, 100 μMZnCl2,
5 μg salmon testis DNA. For the competition assay, 40- and 200-fold
molar excess of unlabeled oligonucleotides (wt or m) was added to
the reaction mixture. Binding reactions were resolved by electropho-
resis in 7.5% polyacrylamide gels in 0.5% Tris-acetate EDTA buffer,
imaged on an Odyssey (LiCor) infrared ﬂuorescence scanner and
quantiﬁed using equipment manufacturer's software. Anti-YY1 anti-
bodies (H-414, Santa Cruz) were used for antibody competition assay.
Knockdown of YY1 mRNA
Transfection of HEK293 cells with 80 pmol (per well) of premade
siRNA duplexes targeting human YY1 mRNA (Santa Cruz) was
performed in 6-well plates using 7 μl (per well) of siRNA Transfection
Reagent (Santa Cruz) according to manufacturer's instructions. As a
control for siRNA transfection we used siRNA-A (Santa Cruz)
consisting of a scrambled sequence. Cells were collected for RNA
extraction 48 h after transfection.
Computational analysis and statistics
For bioinformatic analysis of the GDAP1 promoter region, MatIn-
spector [33], ElDorado and Gene2Promoter (part of the Genomatix
GmbH) software was used. Testing for statistical signiﬁcance was
done by one-way ANOVA followed by Tukey's test as appropriate. A p
value of 0.05 or lower was considered statistically signiﬁcant.
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